We are initiating coverage of Lakewood-Amedex Biotherapeutics, Inc. (LABT) with a $12.00 valuation. Lakewood is a biopharmaceutical company developing a novel class of antimicrobial compounds known as Bisphosphocins , a proprietary platform designed to address one of the largest and fastest-growing challenges in modern healthcare: antimicrobial resistance (AMR). The company's lead clinical candidate, Nu-3, is being developed for the treatment of infected diabetic foot ulcers (iDFU), an indication affecting millions of patients worldwide that continues to have limited treatment options. The company will be initiating a Phase 2a trial of Nu-3 in iDFU in 2026 ahead of a larger placebo controlled Phase 2b program. Positive data from that study would represent a significant inflection point for the company as it would not only support further development of Nu-3 but also provide initial clinical validation for the broader Bisphosphocin platform.
